title: New approaches in the treatment of hepatitis C.
abstract: About 130-170 million people, is estimated to be infected with the hepatitis C virus (HCV). Chronic HCV infection is one of the leading causes of liver-related death and in many countries it is the primary reason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2011 approval was given for the first direct acting antiviral agents (DAA), boceprevir and telaprevir, for treatment of genotype 1, in combination with traditional dual therapy. This strategy managed to increase the rates of sustained viral response (SVR) in both naive patients and in retreated patients, but with greater toxicity, interactions and cost, as well as being less safe in patients with advanced disease, in whom this treatment can trigger decompensation or even death. The recent, accelerated incorporation since 2013 of new more effective DAA, with pan-genomic properties and excellent tolerance, besides increasing the rates of SVR (even up to 100%), has also created a new scenario: shorter therapies, less toxicity and regimens free of PEG/RBV. This has enabled their almost generalised applicability in all patients. However, it should be noted that most of the scientific evidence available is based on expert opinion, case-control series, cohort studies and phase 2 and 3 trials, some with a reduced number of patients and select groups. Few data are currently available about the use of these drugs in daily clinical practice, particularly in relation to the appearance of side effects and interactions with other drugs, or their use in special populations or persons with the less common genotypes. This situation suggests the need for the generalised implementation of registries of patients receiving antiviral therapy. The main inconvenience of these new drugs is their high cost. This necessitates selection and prioritization of candidate patients to receive them, via strategies established by the various national organs, in accordance with the recommendations of scientific societies.
authors.affiliation: Rocío González-Grande, Miguel Jiménez-Pérez, González Arjona, José Mostazo Torres, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo, Hospital Regional Universitario, 29010 Malaga, Spain.
authors.forename: Rocío
authors.initials: R
authors.lastname: González-Grande
authors.affiliation: Rocío González-Grande, Miguel Jiménez-Pérez, González Arjona, José Mostazo Torres, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo, Hospital Regional Universitario, 29010 Malaga, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Jiménez-Pérez
authors.affiliation: Rocío González-Grande, Miguel Jiménez-Pérez, González Arjona, José Mostazo Torres, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo, Hospital Regional Universitario, 29010 Malaga, Spain.
authors.forename: Carolina
authors.initials: C
authors.lastname: González Arjona
authors.affiliation: Rocío González-Grande, Miguel Jiménez-Pérez, González Arjona, José Mostazo Torres, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo, Hospital Regional Universitario, 29010 Malaga, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Mostazo Torres
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D010641:Phenotype; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
keywords: Direct acting antiviral agents; Hepatitis C; Outcome; Patients; Treatment
references.citation: J Hepatol. 2003 Sep;39(3):389-96
references.pmid: 12927925
references.citation: N Engl J Med. 2014 Jan 16;370(3):222-32
references.pmid: 24428468
references.citation: N Engl J Med. 2014 Dec 18;371(25):2375-82
references.pmid: 25386767
references.citation: N Engl J Med. 2013 May 16;368(20):1878-87
references.pmid: 23607594
references.citation: Ann Intern Med. 2015 Jul 7;163(1):1-13
references.pmid: 25909356
references.citation: Ann Rheum Dis. 2014 May;73(5):831-7
references.pmid: 23606708
references.citation: Ann Pharmacother. 2015 Jun;49(6):674-87
references.pmid: 25770114
references.citation: N Engl J Med. 2014 May 15;370(20):1889-98
references.pmid: 24725239
references.citation: J Viral Hepat. 2007 Oct;14(10):697-703
references.pmid: 17875004
references.citation: J Hepatol. 2014 Nov;61(1 Suppl):S45-57
references.pmid: 25086286
references.citation: Curr Opin Virol. 2013 Oct;3(5):514-20
references.pmid: 23896281
references.citation: Lancet. 2013 Jun 15;381(9883):2100-7
references.pmid: 23499440
references.citation: J Hepatol. 2023 Feb;78(2):452
references.pmid: 36464532
references.citation: Lancet. 2014 Aug 2;384(9941):414-26
references.pmid: 24907224
references.citation: J Hepatol. 2015 May;62(5):1204-6
references.pmid: 25559328
references.citation: N Engl J Med. 2014 May 22;370(21):1993-2001
references.pmid: 24795201
references.citation: N Engl J Med. 2011 Jun 23;364(25):2405-16
references.pmid: 21696307
references.citation: World J Hepatol. 2015 Feb 27;7(2):213-25
references.pmid: 25729476
references.citation: Kidney Int. 1994 Dec;46(6):1700-4
references.pmid: 7535369
references.citation: N Engl J Med. 2013 May 16;368(20):1907-17
references.pmid: 23675659
references.citation: J Manag Care Spec Pharm. 2014 Jun;20(6):533-40
references.pmid: 24856591
references.citation: Drugs. 2015 Apr;75(6):675-85
references.pmid: 25837989
references.citation: N Engl J Med. 2011 Mar 31;364(13):1195-206
references.pmid: 21449783
references.citation: Hepatology. 2014 Apr;59(4):1293-302
references.pmid: 24122848
references.citation: Gut. 2014 Feb;63(2):207-15
references.pmid: 24253934
references.citation: Expert Rev Cardiovasc Ther. 2014 May;12(5):533-6
references.pmid: 24725228
references.citation: World J Gastroenterol. 2014 Nov 28;20(44):16409-17
references.pmid: 25469009
references.citation: N Engl J Med. 2014 May 22;370(21):1973-82
references.pmid: 24725237
references.citation: Gastroenterology. 2014 Jul;147(1):132-142.e4
references.pmid: 24704719
references.citation: N Engl J Med. 2014 Apr 24;370(17):1594-603
references.pmid: 24720703
references.citation: N Engl J Med. 2014 May 22;370(21):1983-92
references.pmid: 24795200
references.citation: Lancet. 2015 Mar 21;385(9973):1075-86
references.pmid: 25467591
references.citation: Liver Int. 2015 Jan;35 Suppl 1:21-6
references.pmid: 25529084
references.citation: N Engl J Med. 2013 Jan 3;368(1):34-44
references.pmid: 23281974
references.citation: Nihon Yakurigaku Zasshi. 2015 Mar;145(3):152-62
references.pmid: 25765498
references.citation: Hepatology. 2015 Apr;61(4):1127-35
references.pmid: 25614962
references.citation: Gastroenterology. 2014 Aug;147(2):359-365.e1
references.pmid: 24818763
references.citation: Lancet. 2014 Nov 15;384(9956):1756-65
references.pmid: 25078309
references.citation: Lancet. 2014 Aug 2;384(9941):403-13
references.pmid: 24907225
references.citation: N Engl J Med. 2013 May 16;368(20):1867-77
references.pmid: 23607593
references.citation: N Engl J Med. 2014 Jan 16;370(3):211-21
references.pmid: 24428467
references.citation: Gastroenterology. 2015 Jan;148(1):100-107.e1
references.pmid: 25261839
references.citation: Gastroenterology. 2015 Jan;148(1):108-17
references.pmid: 25304641
references.citation: Lancet. 2015 Mar 21;385(9973):1087-97
references.pmid: 25467560
references.citation: Lancet Infect Dis. 2013 May;13(5):401-8
references.pmid: 23499158
references.citation: Hepatology. 2015 Jun;61(6):1880-6
references.pmid: 25722203
references.citation: J Hepatol. 2015 May;62(5):1040-6
references.pmid: 25450208